CN116903684A - Liver targeting compound and oligonucleotide conjugate and application thereof - Google Patents

Liver targeting compound and oligonucleotide conjugate and application thereof Download PDF

Info

Publication number
CN116903684A
CN116903684A CN202310677873.5A CN202310677873A CN116903684A CN 116903684 A CN116903684 A CN 116903684A CN 202310677873 A CN202310677873 A CN 202310677873A CN 116903684 A CN116903684 A CN 116903684A
Authority
CN
China
Prior art keywords
oligonucleotide
compound
conjugate
formula
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310677873.5A
Other languages
Chinese (zh)
Inventor
李�杰
高慧雅
刘恺悦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongliang Shanghai Biopharmaceutical Technology Co ltd
Original Assignee
Hongliang Shanghai Biopharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongliang Shanghai Biopharmaceutical Technology Co ltd filed Critical Hongliang Shanghai Biopharmaceutical Technology Co ltd
Priority to CN202310677873.5A priority Critical patent/CN116903684A/en
Publication of CN116903684A publication Critical patent/CN116903684A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The application belongs to the technical field of oligonucleotide drug delivery, and relates to a liver targeting compound, a conjugate and application thereof. The application prepares oligonucleotide conjugate with the liver targeting compound, the conjugate realizes the specific targeting delivery of therapeutic oligonucleotide to the inside of liver cells through four N-acetylgalactosamine ligands with specific affinity to asialoglycoprotein receptor on the surface of mammal liver cells in the structure, so as to achieve the purpose of treating diseases, and the conjugate can keep the delivered oligonucleotide highly stable and has excellent delivery efficiency.

Description

Liver targeting compound and oligonucleotide conjugate and application thereof
Technical Field
The application belongs to the technical field of oligonucleotide drug delivery, and particularly relates to a liver targeting compound and a conjugate and application thereof.
Background
Oligonucleotide compounds have medical importance in therapeutic applications, where oligonucleotides and analogs thereof that are expressed only in specific tissues or locations can be selected to treat a disease of interest at a specific target site. Tissue-specific active agents, represented by oligonucleotides and analogs thereof, have made partial progress in their use as therapeutic agents, but there remains a need for improvements in their pharmacological properties for targeted delivery to specific tissues and organs to enhance their biological activity and efficacy. In particular, targeted conjugated delivery techniques targeting the liver are the most widely studied class of delivery systems.
Disclosure of Invention
In view of the deficiencies of the prior art, in a first aspect, the present application provides a liver targeting compound having a structure according to formula (I):
wherein R is 1 The structure is shown as a formula (II), R 2 An atom such as oxygen, sulfur or carbon, preferably a carbon atom; n is any integer from 4 to 10, preferably 4; r is tert-butoxycarbonyl, trityl, 4 '-dimethoxytrityl, 4' or 4 '-trimethoxytrityl, preferably 4,4' -dimethoxytrityl, DMTr; m is H ion, ammonium ion, alkali metal ion or alkaline earth metal ion, etc., preferably H ion;
wherein R is 3 H ion, acetyl, benzyl or t-butoxycarbonyl, etc., preferably acetyl; n is n 1 Is an integer of 1 to 6, preferably 1.
Further, the structural formula of the liver targeting compound is shown as a formula (I-1):
i.e. R 1 The structure is shown as a formula (II), R 2 Is a carbon atom; n is 4; r is DMTr; m is H ion; r is R 3 Acetyl (Ac); n is n 1 1.
In a second aspect, the present application provides an oligonucleotide conjugate having a structure represented by formula (III):
wherein R is 1 The structure is shown as a formula (II), R 2 An atom such as oxygen, sulfur or carbon, preferably a carbon atom; n is 4 to 10, preferably 4; q is a phosphate, carbonate or sulfate, etc., preferably a phosphate; nu is a functional oligonucleotide.
The oligonucleotide conjugate, wherein the functional oligonucleotide Nu is selected from one of small interfering RNA, micro RNA, antisense nucleic acid and mRNA fragment; alternatively, the functional oligonucleotide Nu is a single-stranded oligonucleotide or a double-stranded oligonucleotide.
Further, the oligonucleotide conjugate has a structure as shown in formula (III-1):
alternatively, the functional oligonucleotide is a single-stranded oligonucleotide to the end of which P in formula (III-1) is attached, further to the 3' -end of the single-stranded oligonucleotide; alternatively, the functional oligonucleotide is a double-stranded oligonucleotide comprising a sense strand and an antisense strand, the P-strand in formula (III-1) being attached to the 3' end of the sense strand.
Further, the double stranded oligonucleotide is an siRNA, i.e. a small interfering RNA.
In a third aspect, the present application provides a method of preparing a liver targeting compound of formula (I-1):
compound 10 and compound 6 are prepared into compound 11 under the action of an amide condensing agent, benzyl is removed from the compound 11 through catalytic hydrogenation to obtain compound 12, compound 12 and compound 11 are again reacted with each other under the action of the condensing agent to obtain compound 13 with four target heads, benzyl is removed from the compound 13 through hydrogenation to obtain compound 14, finally compound 14 and compound 12 are reacted to obtain compound 21, compound 21 and succinic anhydride are reacted to introduce ester groups at secondary alcohol positions to obtain compound (I-1), and the reaction formula is shown as follows:
further, the synthesis method of the compound 10 comprises the following steps: the reaction of compound 7 with compound 8 (benzylamine) gives disubstituted compound 9, which is subsequently hydrolyzed to give compound 10, having the formula:
further, the synthesis method of the compound 6 comprises the following steps: the compound 2 reacts with acetic anhydride to obtain an acetyl protected compound 3, the acetyl protected compound is cyclized to obtain a compound 4, the compound 4 reacts with 4- (N-tert-butoxycarbonylamino) -1-butanol to open a ring to obtain a compound 5, and the hydrochloric acid is subjected to Boc protecting group removal to obtain a compound 6, wherein the reaction formula is shown as follows:
in a fourth aspect, the present application provides a method of preparing an oligonucleotide conjugate of formula (iii):
the compound of the formula (I) is connected with controllable microporous glass beads (CPG) solid phase carriers by an amide condensing agent to obtain the solid phase carriers of the compound of the formula (I), and the solid phase carriers are used for preparing oligonucleotide conjugates of the formula (III) by solid phase synthesis.
The compounds of formula (I) prepare conjugates of formula (III) which deliver therapeutic oligonucleotides into the interior of hepatocytes for the purpose of treating diseases by means of four N-acetylgalactosamine ligands in the structure having specific affinity for asialoglycoprotein receptors on the surface of mammalian hepatocytes.
Further, the preparation method of the oligonucleotide conjugate of the formula (III-1) comprises the steps that the compound of the formula (I-1) is connected with a controllable microporous glass bead (CPG) solid phase carrier by an amide condensing agent to obtain the solid phase carrier of the formula (III' -1) of the compound of the formula (I-1), and the solid phase carrier is used for preparing the oligonucleotide conjugate of the formula (III-1) by solid phase synthesis, wherein the reaction formula is as follows:
in a fifth aspect, the present application provides the use of a liver targeting compound of formula (I) and an oligonucleotide conjugate of formula (III) in the preparation of an oligonucleotide drug.
Further, the oligonucleotide specific target gene of the oligonucleotide drug is selected from at least one of PCSK9, HBV, TTR, and AGT.
The beneficial effects of the application are as follows:
compared with the existing structure, the compound of the formula (I) provided by the application has a novel four-target structure, and the preparation method is simple and controllable, low in cost and simple in synthetic route. The application provides a compound of formula (I) and a preparation method thereof, wherein the compound of formula (I) is used for preparing a conjugate of formula (III), the synthetic route and the purification steps of the conjugate of formula (III) are simple, the cost is low, and simultaneously, four N-acetylgalactosamine ligands with specific affinity to asialoglycoprotein receptors on the surfaces of liver cells of mammals in the structure realize the specific targeted delivery of therapeutic oligonucleotides into the liver cells so as to achieve the purpose of treating diseases, and the conjugate of formula (III) can keep the delivered oligonucleotides highly stable and has excellent delivery efficiency.
Drawings
FIG. 1 is a bar graph showing TTR mRNA expression in mice according to an embodiment of the present application;
FIG. 2 is a bar graph showing TTR protein expression in mice in accordance with an embodiment of the present application.
Detailed Description
The principles and features of the present application are described below in connection with examples, which are set forth only to illustrate the present application and not to limit the scope of the application.
Examples:
1. preparation of compound 10:
compound 7 (methyl 6-bromo-hexanoate, 7.33g,35.0 mmol), compound 8 (benzylamine, 1.5g,14.0 mmol), anhydrous potassium carbonate (5.8 g,42.0 mmol), potassium iodide (1.16 g,7.0 mmol) were weighed into a reaction flask, 50mL of absolute ethanol was added and stirred and suspended, and the reaction system was heated under stirring at 82 ℃ under reflux to react for 12h. Stopping heating, cooling to room temperature, removing solvent ethanol under reduced pressure, adding 30mL of water and 30mL of dichloromethane, stirring, standing and layering, separating out an organic phase, extracting an aqueous phase with dichloromethane for 2 times, combining the organic phases, and drying and desolventizing to obtain crude yellow oily liquid. Column chromatography purification, eluting with petroleum ether: ethyl acetate=10:1-3:1 gradient, gave compound 9 as a pale yellow oily liquid 3.71g in 73% yield.
Compound 9 (3.7 g,10.17 mmol) is weighed and placed in a reaction bottle, 10mL of ethanol is added for stirring and dissolution, sodium hydroxide (1.63 g,40.68 mmol) is weighed and added into the reaction liquid, the reaction system is heated and stirred for 2 hours at 40 ℃, heating is stopped and cooled to room temperature, the solvent ethanol is removed under reduced pressure, after water is added for dissolution, the phase dichloromethane is washed for 2 times, the pH of the water phase is adjusted to 2-3 by 1N hydrochloric acid, solid sodium chloride is added until saturation, the dichloromethane is added for extracting the product for 3 times, the organic phases are combined, and after drying, the solvent is removed, the product intermediate 10 is obtained as yellow oily liquid 2.63g, and the yield is 77%.
MS m/z[M+H]+(ESI):336.05。
2. Preparation of Compound 6
Compound 2 (50.0 g,232 mmol) was added to the flask, acetic anhydride (165 mL) was added, pyridine (220 mL) was added with ice-bath, DMAP (2.4 g,19.7 mmol), and triethylamine (23.5 g,232 mmol). Stir overnight at room temperature after addition. Filtration, washing the filter cake with toluene, washing with water, and drying under reduced pressure at 45℃gave compound 3 as a white solid, 73.2g, in 81% yield.
Compound 3 (20.0 g,51.4 mmol) was added to the reaction flask and 4A molecular sieve dried dichloromethane (100 mL) was added. Trimethylsilicone triflate (13.7 g,61.7 mmol) was added under argon and stirred overnight at room temperature. Triethylamine (15.6 g,154.2 mmol) was added and stirred. The solvent and triethylamine were removed under reduced pressure to give compound 4 as an oil (32.1 g) which was directly fed to the next reaction without purification.
Compound 4 of the above step was dissolved in 1, 2-dichloroethane (120 mL) dried over 4A molecular sieve, 4- (N-t-butoxycarbonylamino) -1-butanol (10.2 g,54 mmol) was added, and trimethylsilyl triflate (2.3 g,10.3 mmol) was added continuously at room temperature and stirred overnight. To the reaction solution was added saturated sodium hydrogencarbonate solution (60 mL), water (80 mL), the mixture was separated, the organic phase was washed with water (80 mL. Times.1), 10% aqueous citric acid solution (100 g. Times.2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to give crude product 5 as a tan oil (16.5 g). The yield of the two steps is 62%.
Compound 5 (16.0 g,30.8 mmol) was added to the reaction flask, dioxane hydrochloride solution (4.0 mol/L,65 mL) was added, and the mixture was stirred at room temperature for 3h. The solvent was removed under reduced pressure to give amber foam compound 6, 12.3g in 95% yield. This compound was used in the next reaction without purification.
MS m/z[M+H]+(ESI):418.06。
3. Preparation of Compounds of formula (I-1)
To the reaction flask was added compound 10 (6.0 g,17.9 mmol) and dissolved in dichloromethane (90 mL). N, N-diisopropylethylamine (9.2 g,71.1 mmol) was added and HATU (2- (7-azabenzotriazol) -N, N, N ', N' -tetramethyluronium hexafluorophosphate, 14.3g,37.6 mmol) was added and stirred at room temperature for 3h. Compound 6 (15.7 g,37.6 mmol) was dissolved in methylene chloride (60 mL), and the solution was added dropwise to the reaction system and reacted at room temperature under stirring for 4 hours. 100mL of saturated sodium chloride solution is added, the mixture is separated, the dichloromethane phase anhydrous sodium sulfate is dried, and the solvent is removed under reduced pressure to obtain a red oily crude product. 30mL of methylene chloride and 120mL of methyl tertiary butyl ether are added, stirred for 1h, and filtered to obtain a yellow solid. The above crystallization operation was repeated twice to obtain 11,9.1g of compound in 45% yield.
Compound 11 (9.0 g,7.9 mmol) was added to the reaction flask, 100mL of water was added, and the mixture was dissolved with stirring. 5% Pd-C (1.0 g) was added and hydrogen was bubbled through at room temperature for 3h. Pd-C was removed by filtration, sodium chloride solid was added to water to saturation and extracted with dichloromethane (70 mL. Times.4). The organic phases were combined, dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure to give 8.0g of compound 12 as an off-white solid in 96% yield.
Compound 10 (1.27 g,3.8 mmol) was added to the reaction flask and 10mL of dichloromethane was added and stirred. HATU (3.03 g,8 mmol) was added and stirred at room temperature for 3h. Compound 12 (7.95 g,7.6mmol, dissolved in 20mL of dichloromethane) was added and reacted at room temperature for 2h. 100g of 10% sodium chloride solution was added, the mixture was separated, a methylene chloride phase was separated, the 10% sodium chloride solution was washed (50 g. Times.4), the methylene chloride phase was dried over anhydrous sodium sulfate, the solvent was removed under reduced pressure to obtain a crude brown solid, 10mL of methylene chloride and 100mL of ethyl acetate were added, and the mixture was stirred, and the supernatant was poured off to obtain a gummy solid from the bottom of the bottle. 25mL of acetonitrile was added, the gummy solid was dissolved by sonication, allowed to stand overnight, and filtered to give a gummy solid. The above crystallization operation was repeated three times to obtain 2.81g of pale yellow gummy solid, yield 31%, i.e. compound 13.
Compound 13 (2.75 g,1.15 mmol) was added to the reaction flask, 5% Pd-C (0.7 g) was added and hydrogen was bubbled at room temperature for 3h. Pd-C was removed by filtration, sodium chloride solid was added to water to saturation and extracted with dichloromethane (20 mL. Times.4). The organic phases were combined, dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure to give 2.51g of a tan solid in 95% yield, compound 14.
Compound 20 (672 mg,1.1 mmol) was added to the reaction flask, dichloromethane 5mL was added, HATU (543 mg,1.43 mmol) was added and stirring was continued for 3h at room temperature. Compound 14 (2.50 g,1.09mmol, in 5mL of dichloromethane) was added to the reaction and stirred at room temperature for 3h. 10g of 10% sodium chloride solution was added to the reaction, the mixture was stirred and separated, the organic phase was washed with 10% sodium chloride solution (10 g. Times.3), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to give a brown oily substance. 4mL of methylene chloride and 30mL of ethyl acetate were added, and a solid was precipitated and filtered to obtain 725mg of an off-white solid, the yield was 23%, namely, compound 21.
Compound 21 (620 mg,0.21 mmol) was added to the reaction flask, and 5mL of methylene chloride was added. Succinic anhydride (210 mg,2.1 mol), DMAP (4-dimethylaminopyridine, 256mg,2.1 mmol), triethylamine (323 mg,3.2 mmol) were added continuously, the reaction was allowed to proceed to completion at room temperature for 24h, and LC-MS monitored. 10g of a 10% sodium chloride solution was added to the reaction mixture, and the organic phase was separated and washed with saturated sodium chloride (8 g. Times.3). The organic phase is dried over anhydrous sodium sulfate, and the solvent is removed under reduced pressure to obtain a crude product. 8mL of methylene chloride was added to dissolve, 100mL of ethyl acetate was added thereto, and the mixture was precipitated as a solid, which was dried under reduced pressure to give solid 580mg, purity 71% at 214 nm.
Preparing liquid phase for separation and purification, wherein the model is Gilson GX281, and the chromatographic column is as follows: waters X-bridge C18, 19X 250mm,10 μm. Mobile phase a: ammonium bicarbonate aqueous solution, ph=8-9; fluidity B: acetonitrile. The flow rate is 20mL/min, the monitoring wavelength is 214nm, the sample injection amount per needle is 6.0 mu l, and the gradient elution is carried out, so that 180mg of white solid powder is obtained, namely the compound (I-1) with the HPLC purity of 98.84 percent.
HRMS m/z[M-H]-(ESI):2988.3838。 1 H NMR(400MHz,Chloroform-d)δδ7.90–7.79(m,9H),7.36–7.25(m,4H),7.25–7.14(m,5H),6.91–6.82(m,4H),5.24(t,J＝7.0Hz,4H),5.18(t,J＝6.6Hz,4H),5.03(d,J＝5.5Hz,4H),4.99(p,J＝4.4Hz,1H),4.25(qd,J＝12.1,4.3Hz,8H),4.11(ddd,J＝9.1,7.1,5.5Hz,4H),3.96(dt,J＝6.4,4.4Hz,4H),3.90–3.78(m,8H),3.71–3.58(m,8H),3.52(qdd,J＝13.6,6.1,4.4Hz,2H),3.28–3.16(m,20H),2.77–2.63(m,4H),2.43(tt,J＝8.1,1.3Hz,6H),2.21(dt,J＝16.9,8.4Hz,10H),2.09(d,J＝15.6Hz,36H),2.02(s,12H),1.72–1.50(m,45H),1.46–1.28(m,24H).
4. Synthesis of solid Carrier of Compound (I-1)
Compound (I-1) (59.8 mg, 20. Mu. Mol) was added to DMF 10mL, and benzotriazol-N, N, N ', N' -tetramethyluronium hexafluorophosphate (HBTU, 19mg, 50. Mu. Mol), N, N-diisopropylethylamine (DIEA, 16.2mg, 125. Mu. Mol) was added to an amino-modified solid support (CPG-NH) 2 ) 0.4g, and the reaction was carried out with shaking at 25℃for 24h. After the completion of the reaction, it was washed with acetonitrile and dichloromethane in this order. The reaction was continued with the addition of 20% acetic anhydride/80% acetonitrile at 25℃for 24h with shaking. After the reaction is completed, the solid phase carrier target product is obtained by washing with acetonitrile and dichloromethane in sequence, and the GalNAc loading is measured to be 24.38 mu mol/g.
Preparation of siRNA conjugates
siRNA targeting the mouse TTR gene was synthesized, and the 3' -end of the SS chain linked to a galactose molecular cluster (compound of formula (I-1)).
SS chains (5 '-3'):
AmsAmsCmAmGmUmGfUmUfCfUfUmGmCmUmCmUmAmUmAmAm(SEQ ID NO 1)
AS chains (5 '-3'):
UsUfsAmUmAmGfAmGmCmAmAmGmAmAfCmAfCmUmGmUmUmsU msUm(SEQ ID NO 2)
wherein the lowercase letter f indicates that one nucleotide adjacent to the left side of the letter f is a 2 '-fluoro-modified nucleotide, the lowercase letter a, g, c, u is a 2' -OMe-modified nucleotide, and the lowercase letter s indicates that two nucleotides adjacent to the left and right sides of the letter s are connected by a phosphorothioate diester linkage.
Nucleoside phosphoramidite monomers such as 2' -O-methyl, which are nucleoside monomer raw materials for siRNA synthesis, are purchased from Shanghai megawatt technology development Co.
3% dichloroacetic acid is used as a deprotection agent, 0.25M 5-ethylthio-1H-tetrazole acetonitrile solution is used as an activating agent, pyridine solution of N, N-dimethyl-N' - (3-thio-3H-1, 2, 4-dithiozol-5-yl) formamidine is used as a vulcanizing agent, 0.05M iodine/pyridine/water solution is used as an oxidizing agent, 20% acetic anhydride acetonitrile solution is used as a capping agent A,20% acetonitrile/N-methylimidazole/pyridine solution is used as a capping agent B, and the relevant synthetic reagents are purchased from Ke Lema Biotechnology Co., ltd.
Each RNA single strand was synthesized using a phosphoramidite solid phase, starting with a solid phase support, and using a DNA synthesizer to attach nucleoside phosphoramidite monomers according to the synthesis procedure. Each nucleoside monomer is connected by four steps of deprotection, coupling, oxidation or sulfuration and capping.
After the solid phase synthesis, the oligonucleotide was ammonolyzed with 28% ammonia at 55℃for 16h. The supernatant was concentrated and evaporated to dryness, purified using a Resource 15Q column, eluted by a gradient of sodium bromide solution, and DMTr was removed using a 3% trifluoroacetic acid solution, and purified to obtain the oligonucleotide chains. Collecting eluent, desalting by using a sephadex G25 gel column, collecting the obtained oligonucleotide chain, freeze-drying, detecting the purity by ion pair chromatography, and analyzing the molecular weight of a target product by mass spectrometry. The single-stranded oligonucleotides obtained by ultraviolet quantification are complementarily paired according to the equimolar ratio, are dissolved in water, form double-stranded siRNA according to the conventional annealing method, and are adjusted to the concentration required by experiments for standby.
And (3) testing:
1. inhibition of TTR mRNA expression in mice
C57BL/6 mice (Ji Cui Ji kang, SPF, female) at 8 weeks of age were used and randomly grouped. On day 0, each siRNA conjugate was administered to the skin of the neck of the shoulder of the mouse, and at the same time, physiological saline was administered as a control group. At days 0, 7, 14, 21, 28, 3 mice were euthanized for each group, and liver tissue samples were taken. mRNA expression levels of TTR in mouse liver tissues were detected using a real-time fluorescent PCR method. Total liver RNA was extracted using RNAeasy Mini kit (Qiagen, cat. No. 74104) and cDNA was reverse transcribed according to High Capacity cDNA Reverse Transcription Kits (Thermo Fisher, cat. No. 4368814) for RT-PCR. Using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as an internal gene, mRNA expression levels were detected by using Taqman probe primers (Table 2) of mouse TTR and GAPDH, respectively, according to the RT-PCR method shown in Table 1. The delta Ct method is adopted to calculate the expression quantity of the TTR mRNA of the mice, and the effect of the I-1-siRNA on inhibiting the TTR mRNA is calculated.
TABLE 1 real-time fluorescent quantitative PCR conditions
TABLE 2 detection primer sequences
FIG. 1 is a bar graph of TTR mRNA expression in mice in the examples of the present application, showing that the conjugates of the present application have the ability to deliver small nucleic acids directed to the liver and have good TTR mRNA inhibitory activity in vivo. Further illustrates that the conjugate connected with siRNA can improve the targeting property and stability of the oligonucleotide drug to liver cells by utilizing the structural characteristics of the conjugate, and can effectively solve the drug delivery problem.
2. Inhibition of TTR protein expression in mice
C57BL/6 mice (Ji Cui Ji kang, SPF, female) at 8 weeks of age were used and randomly grouped. On day 0, 100. Mu.L of each siRNA conjugate was administered to the skin of the neck of the shoulder of the mouse, and at the same time, physiological saline was administered as a control group. Plasma samples were taken at days 0, 7, 14, 21 and 28, respectively, and the TTR protein content in the plasma was measured by ELISA, and normalized with the 0 day plasma TTR protein amount.
Figure 2 is a bar graph of TTR protein expression in mice in an embodiment of the application, showing that the conjugates of the application have the ability to deliver small nucleic acids directed to the liver, capable of significantly inhibiting TTR protein expression.
It will be understood that the application has been described in terms of several embodiments, and that various changes and equivalents may be made to these features and embodiments by those skilled in the art without departing from the spirit and scope of the application. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the application without departing from the essential scope thereof. Therefore, it is intended that the application not be limited to the particular embodiment disclosed, but that the application will include all embodiments falling within the scope of the appended claims.

Claims (9)

1. A liver targeting compound characterized by having a structure represented by formula (I):
wherein R is 1 The structure is shown as a formula (II), R 2 Is oxygen, sulfur or a carbon atom; n is any integer from 4 to 10; r is tert-butoxycarbonyl, trityl, 4 '-dimethoxytrityl or 4,4' -trimethoxytrityl; m is H ion, ammonium ion, alkali metal ion or alkaline earth metal ion;
wherein R is 3 Is H ion, acetyl, benzyl or tert-butoxycarbonyl; n is n 1 Is any integer from 1 to 6.
2. The liver targeting compound of claim 1 having the structural formula (I-1):
3. an oligonucleotide conjugate, characterized by having a structure represented by formula (iii):
wherein R is 1 The structure is shown as a formula (II);R 2 is oxygen, sulfur or a carbon atom; n is any integer from 4 to 10; q is phosphate, carbonate or sulfate; nu is a functional oligonucleotide.
4. The oligonucleotide conjugate according to claim 3, characterized in that the conjugate has a structure represented by formula (iii-1):
5. the conjugate of claim 3, wherein the functional oligonucleotide is one of a small interfering RNA, a microrna, an antisense nucleic acid, or an mRNA fragment.
6. A conjugate according to claim 3, wherein the functional oligonucleotide is a single-stranded oligonucleotide or a double-stranded oligonucleotide.
7. The conjugate of claim 6, wherein the double stranded oligonucleotide is an siRNA.
8. Use of the liver targeting compound of any of claims 1-2 or the oligonucleotide conjugate of any of claims 3-7 in the preparation of an oligonucleotide drug.
9. The use according to claim 8, wherein the oligonucleotide specific target gene of the oligonucleotide drug is selected from at least one of PCSK9, HBV, TTR and AGT.
CN202310677873.5A 2023-06-08 2023-06-08 Liver targeting compound and oligonucleotide conjugate and application thereof Pending CN116903684A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310677873.5A CN116903684A (en) 2023-06-08 2023-06-08 Liver targeting compound and oligonucleotide conjugate and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310677873.5A CN116903684A (en) 2023-06-08 2023-06-08 Liver targeting compound and oligonucleotide conjugate and application thereof

Publications (1)

Publication Number Publication Date
CN116903684A true CN116903684A (en) 2023-10-20

Family

ID=88363719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310677873.5A Pending CN116903684A (en) 2023-06-08 2023-06-08 Liver targeting compound and oligonucleotide conjugate and application thereof

Country Status (1)

Country Link
CN (1) CN116903684A (en)

Similar Documents

Publication Publication Date Title
CN109462981B (en) Targeting ligands
CN109069529B (en) Targeting ligands for therapeutic compounds
US9695211B2 (en) Method for the synthesis of phosphorus atom modified nucleic acids
KR20230119637A (en) Poly-morpholino oligonucleotide gapmer
CN116903684A (en) Liver targeting compound and oligonucleotide conjugate and application thereof
JP2024508780A (en) Compositions for conjugating oligonucleotides and carbohydrates
JP2024515734A (en) Conjugates, methods of making and uses thereof
CN114763547A (en) Angiotensinogen-targeting nucleic acids and uses thereof
CN110603330B (en) Oligonucleotide derivative or salt thereof
TW202123973A (en) Conjugate of galnac-oligonucleotide for delivery to liver and manufacturing method thereof
CN117466959A (en) Liver targeting compound, conjugate and application
CN113292616B (en) Monosaccharide ligand functionalized cationic lipid compound and preparation method and application thereof
CN116732034A (en) Oligonucleotide for inhibiting AGT gene or pharmaceutically acceptable salt thereof and application
CN117624266A (en) Liver targeting compound, oligonucleotide conjugate thereof, coupling method and application
WO2024040531A1 (en) Novel compositions for conjugating oligonucleotides and carbohydrates
CN117305301A (en) Oligonucleotide for inhibiting ASGPR-1 gene or pharmaceutically acceptable salt thereof and application
WO2024002007A1 (en) Double-stranded rna comprising nucleotide analog capable of reducing off-target toxicity
CN117881783A (en) siRNA for inhibiting apoptosis-ligand 1 gene expression, conjugate, pharmaceutical composition and application thereof
CN117561268A (en) Targeting ligands and uses thereof
TW202408490A (en) Novel compositions for conjugating oligonucleotides and carbohydrates
WO2023241591A1 (en) Sirna molecule for regulating pcsk9 gene activity
WO2023250368A2 (en) Atxn2 rna interference agents
CN116854754A (en) GalNAc compound containing ribose ring or derivative structure thereof and oligonucleotide conjugate thereof
CN117580846A (en) Compounds with liver targeted delivery effect and oligonucleotide conjugates thereof
EA043375B1 (en) TARGETTING LIGANDS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination